9th Conference on Recombinant Protein Production (RPP9) 

Dubrovnik, 2017 


A pre-conference session, open to all congress participants, is scheduled on April 23rd. Young researchers from different international PhD programmes (BioToP and the Innovative Training Network ITN) will give a short presentation of their current work in the field of strain engineering and improvement for recombinant protein production. 


About BioToP

The PhD programme BioToP is a research-based doctoral education at the interface of basic and applied science in the field of protein biotechnology at the Vienna Institute of Biotechnology (VIBT) at BOKU, Vienna. BioToP provides comprehensive training in the fields of 

  • structure-function analysis, engineering and design of proteins,
  • protein synthesis, targeting and post-translational modifications,
  • expression systems and cell factories as well as
  • bioinformatics and molecular modelling.

For further information please visit the BioToP homepage




The Marie Skłodowska-Curie Innovative Training Networks (ITN-ETN) aim to train a new generation of creative, entrepreneurial and innovative early-stage researchers (typically PhD and Masters’ Degree students), able to face current and future challenges and to convert knowledge and ideas into products and services for economic and social benefit. 


About ProteinFactory

The ProteinFactory partnership ‘Engineering of new-generation protein secretion systems’ builds new-generation platforms for bacterial protein secretion and trains a cohort of young scientists in the field of recombinant protein production. The ProteinFactory partnership involves six academic institutions and five biotech companies. A total of 15 Early Stage Researchers is appointed on the project.

For further information please visit the ProteinFactory homepage


About eCHO Systems

The eCHO Systems ITN is a collaborative effort of four academic and 15 industrial partners, jointly training 15 PhDs, seeking to significantly advance the CHO cell platform for production of biopharmaceuticals. Chinese hamster (CHO) ovary cells are the production host for a +50 billion €/yr biopharmaceuticals market. Our primary goal is the development and application of synthetic and systems biology tools to develop the next generation of these cell factories.

For further information please visit the eCHO homepage